Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union Health Ministry seeking the inclusion of its Covid-19 vaccine, Covovax, on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday.
The letter was written by Prakash Kumar Singh, Director, Serum Institute of India, on March 27, they said.
Last month, the Covid-19 Working Group, headed by Dr. N. K. Arora, also recommended to the health ministry the inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults who have been vaccinated with two doses of either Covishield or Covaxin.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
-
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
The Drugs Controller General of India had approved the market authorization for Covovax for those who had been administered two doses of either Covishield or Covaxin. Also, Covovax has been approved by the World Health Organisation and the U.S. Food and Drug Administration.
The DCGI had approved Covovax for restricted use in emergency situations in adults on Dec. 28, 2021; in the 12–17 age group on March 9, 2022; and in the 7–11 age group on June 28, 2022, subject to certain conditions.
Covovax is manufactured through a technology transfer from U.S.-based vaccine maker Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. It was granted an emergency use listing by the WHO on Dec.17, 2021.
In August 2020, Novavax Inc. announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in India and other low- and middle-income countries.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
